COMPARISON
Exenatide vs Pramlintide
5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.
Answer
Exenatide is authorised or registered in 5 and Pramlintide in 1 of the 10 registers read. Exenatide: highest phase Phase 2. Pramlintide: highest phase Phase 3 (1 phase 3 trial, 0 with posted results). 3 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Exenatide | Pramlintide | |
|---|---|---|
| Registered trials differs | 383 clinicaltrials.gov · 2026-10-03 | 65 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Byetta openfda · 2026-10-03T17:23:44.062Z | FDA-approved: SymlinPen openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation differs | Withdrawn ema · 2026-10-03 | Nothing on record ema read 2026-08-31 |
| EU withdrawn on differs | 2024-11-20 ema · 2026-10-03 | Not checked no record of "withdrawnOn" for pramlintide |
| ATC code differs | A10BJ01 ema · 2026-10-03 | Not checked no record of "atcCode" for pramlintide |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Exenatide | placebo | Pramlintide | placebo |
|---|---|---|---|---|
| Headache | 1.9% | 1.3% | - | - |
| Non-cardiac chest pain | 1.1% | 1.0% | - | - |
| Osteoarthritis | 0.9% | 1.0% | - | - |
| Dizziness | 0.8% | 0.4% | - | - |
| Constipation | 0.8% | 0.3% | - | - |
| Dyspepsia | 0.8% | 0.3% | - | - |
| Chronic obstructive pulmonary disease | 0.7% | 0.7% | - | - |
| Fatigue | 0.6% | 0.1% | - | - |
| Back pain | 0.5% | 0.6% | - | - |
| Sinusitis | 0.5% | 0.2% | - | - |
| nausea | - | - | 28.5% | 4.7% |
| injection site pruritus | - | - | 14.7% | 0.7% |
| injection site erythema | - | - | 14.5% | 0.9% |
| Upper respiratory tract infection | - | - | 12.1% | 10.4% |
| injection site bruising | - | - | 11.2% | 12.3% |
| injection site hemorrhage | - | - | 11.2% | 3.8% |
| injection site rash | - | - | 8.9% | 0.0% |
| injection site urticaria | - | - | 8.3% | 0.0% |
| nasopharyngitis | - | - | 6.6% | 7.5% |
| injection site nodule | - | - | 5.9% | 3.8% |
Trial register Exenatide: 24 placebo-controlled trials; Pramlintide: 5. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Exenatide side effects · Pramlintide side effects
LEGAL STATUS
Approval in each country read
| Country | Exenatide | Pramlintide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Withdrawn | Not on the register | Regulator EMA |
| United Kingdom | Authorised | Not on the register | Regulator MHRA |
| Canada | Authorised | Not on the register | Regulator Health Canada |
| Australia | Status unknown | Status unknown | TGA |
| Switzerland | Not on the register | Not on the register | Regulator Swissmedic |
| Brazil | Registado | Not on the register | Regulator ANVISA |
| Serbia | Not on the register | Not on the register | Regulator ALIMS |
| Singapore | Not on the register | Not on the register | Regulator HSA |
| Turkey | Ruhsatli | Not on the register | Regulator TITCK |
HEAD TO HEAD
3 registered trials include both
| NCT01269047 | Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia COMPLETED · updated 2018-04-12 |
|---|---|
| NCT01269008 | Closed Loop System With Pramlintide Versus Exenatide COMPLETED · updated 2018-02-20 |
| NCT00950677 | The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes COMPLETED · updated 2017-04-24 |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.